MediSieve presented the company’s journey at the launch of London Business School's Innovation to Market Programme and later listened to an excellent panel with LBS alumni in December 2021.

London Business School's Innovation to Market Programme is a new course for early-career researchers and MBAs run by Professor Jeff Skinner. The course is available as an MBA elective and is open to external applications free of charge. The course aims to build well-balanced teams around technologies that are ripe for commercialisation by bringing together researchers and MBA students. MediSieve was used as a case study for the programme launch. Its CEO & Founder, Dr George Frodsham, was invited to talk about his journey of spinning out and building a company.

Later that day a panel with fellow LBS alumni from renowned venture capital funds was held. The participants included Miao He from Hadean Ventures,  Lavanya Bhamidipati from InHealth Ventures, and Georg Glatz from IQ Capital. The team of MediSieve was glad to take part in the launch of the Innovation to Market Programme and is looking forward to see new exciting companies originate from it.

More about the programme:

https://www.london.edu/faculty-and-research/strategy-and-entrepreneurship/innovation-to-market

About MediSieve

MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked